S3. Temporal effect of the combination of AZD5363 with endocrine therapy on PI3K/mTOR/AKT, ER and cell cycle signalling. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Autor: Lesley-Ann Martin, Mitch Dowsett, Barry R. Davies, Stephen Johnston, Gianmaria Liccardi, Aradhana Rani, Hayley Campbell, Urszula M. Polanska, Nikiana Simigdala, Aurélie Thuleau, Qiong Gao, Elisabetta Marangoni, Stephanie K. Guest, Sunil Pancholi, Ricardo Ribas
Rok vydání: 2023
DOI: 10.1158/1535-7163.22502731
Popis: (A) MCF7 and MCF7-LTED were treated for 1, 8 and 24-hours with the drug combinations indicated (B) T47D, T47D-LTED, ZR75., ZR75-LTED and TamR cell lines were treated for 1-hour as indicated and signalling pathways analysed by immunoblotting. (C) MCF7 and MCF7-LTED cells were treated with the drug combinations indicated for 48-hours and FACS analysis used to measure changes in S-phase . Error bars represent {plus minus} SEM. *p
Databáze: OpenAIRE